Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

NCT05856695 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Carboplatin + Paclitaxel + Durvalumab

Sponsor

Intergroupe Francophone de Cancerologie Thoracique